

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for treating an inflammatory skin or mucous membrane disease, comprising administering intradermally to a subject in need thereof an effective amount of hyaluronic acid in crosslinked form, which is not administered in conjunction with a penetration-promoting agent,

wherein the inflammatory skin or mucous membrane disease is pruritus, prurigo, urticaria, psoriasis, psoriasis vulgaris, vitiligo, a viral skin disease which leads to wart formation, verruca vulgaris, Condylomata accuminata, rosacea, perioral dermatitis, or a chronic or acute ulceration of the skin.

2. (Previously Presented) A method according to claim 1, wherein administering is by local administration.

3. (Previously Presented) A method according to claim 1, wherein administering is to the border of the dermoepithelial transition.

4. (Previously Presented) A method according to claim 1, wherein the degree of crosslinking is 0.1% to 10%.

5. (Currently Amended) A method for treating an inflammatory skin or mucous membrane disease, comprising administering intradermally to a subject in need thereof an effective amount of a mixture comprising crosslinked and uncrosslinked hyaluronic acid,

wherein the inflammatory skin or mucous membrane disease is atopic dermatitis, eczema, seborrheic or microbial eczema, pruritus, prurigo, urticaria, red lichen, psoriasis, psoriasis vulgaris, vitiligo, a viral skin disease which leads to wart formation, verruca vulgaris, Condylomata accuminata, rosacea, perioral dermatitis, acne, acne vulgaris, acne conglobata, or a chronic or acute ulceration of the skin.

6. (Previously Presented) A method according to claim 5, wherein the

uncrosslinked hyaluronic acid is

- (i) long-chain hyaluronic acid having an average molecular weight (weight-average) of at least 200 kD, or
- (ii) short-chain hyaluronic acid having an average molecular weight (weight-average) up to 50 kD, or
- (iii) a mixture thereof.

7. (Withdrawn) A method according to claim 1, wherein the hyaluronic acid is in a composition which contains an inhibitor of hyaluronic acid degradation.

8. (Withdrawn) A method according to claim 7, wherein the inhibitor of hyaluronic acid degradation is heparin, indomethacin, a salicylate, a free radical trap, or vitamin A, C or E, or a mixture thereof.

9. (Previously Presented) A method according to claim 1, wherein the hyaluronic acid is present as an injectable preparation.

10. (Withdrawn) A method according to claim 1, wherein the hyaluronic acid is in a composition which contains a further glycosaminoglycan in crosslinked or uncrosslinked form.

11. (Cancelled)

12. (Previously Presented) A method according to claim 1, wherein the subject is a human.

13. (Previously Presented) A method according to claim 1, wherein the subject is a veterinary patient.

14-21. (Cancelled)

22. (Withdrawn and Currently Amended) A method according to claim 5 ~~claim 1~~, wherein the inflammatory skin or mucous membrane disease is atopic dermatitis.

23. (Previously Presented) A method according to claim 1, wherein the inflammatory skin or mucous membrane disease is a viral skin disease which leads to wart formation.

24. (Withdrawn and Currently Amended) A method according to claim 5 ~~claim 1~~, wherein the inflammatory skin or mucous membrane disease is acne vulgaris.

25. (Currently Amended) A method for treating an inflammatory skin or mucous membrane disease, comprising administering intradermally to a subject in need thereof an effective amount of a mixture comprising crosslinked and uncrosslinked hyaluronic acid, wherein the uncrosslinked hyaluronic acid is

(a) short-chain hyaluronic acid having an average molecular weight (weight-average) up to 50 kD, or

(b) a mixture of long-chain hyaluronic acid having an average molecular weight (weight-average) of at least 200 kD, and short-chain hyaluronic acid having an average molecular weight (weight-average) up to 50 kD,

wherein the inflammatory skin or mucous membrane disease is atopic dermatitis, eczema, seborrheic or microbial eczema, pruritus, prurigo, urticaria, red lichen, psoriasis, psoriasis vulgaris, vitiligo, a viral skin disease which leads to wart formation, verruca vulgaris, Condylomata accuminata, rosacea, perioral dermatitis, acne, acne vulgaris, acne conglobata, or a chronic or acute ulceration of the skin.

26. (Cancelled)